A comparison of the inflammatory control of asthma provided by one inhalation of Symbicort Turbuhaler 160/4.5 microg/inhalation b.i.d. plus as-needed versus one inhalation of Symbicort Turbuhaler 320/9 microg/inhalation b.i.d. + one inhalation of Pulmicort Turbuhaler 400 microg/dose b.i.d. plus terbutaline Turbuhaler 0.4 mg/inhalation as-needed. A 12-month, randomised, double-blind, parallel-group, active controlled, multinational, phase III B study in adult patients with asthma, EOS

Trial Profile

A comparison of the inflammatory control of asthma provided by one inhalation of Symbicort Turbuhaler 160/4.5 microg/inhalation b.i.d. plus as-needed versus one inhalation of Symbicort Turbuhaler 320/9 microg/inhalation b.i.d. + one inhalation of Pulmicort Turbuhaler 400 microg/dose b.i.d. plus terbutaline Turbuhaler 0.4 mg/inhalation as-needed. A 12-month, randomised, double-blind, parallel-group, active controlled, multinational, phase III B study in adult patients with asthma, EOS

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Budesonide; Budesonide/formoterol; Terbutaline
  • Indications Asthma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Jan 2008 Status changed from in progress to completed.
    • 17 Nov 2006 Status change
    • 22 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top